Table 6.

Summary of the utilities for health states of schizophrenia.

Study	Stable	Non-hospitalized relapse	Hospitalized relapse	References
Einarson et al. (15)	0.89	0.659	0.49	(45–49)
Lachaine et al. (16)	0.75	NA	NA	(45)
Park et al. (17)	0.856	NA	−0.358	(46)
Dilla et al. (18)	0.77	—	−0.18	From SOHO data
Druais et al. (21)	0.919	0.762	0.604	(46)
Lin et al. (22)	0.8	NA	0.67	(45)
Rajagopalan et al. (23)	0.799	NA	0.67	(45, 46, 50)
Einarson et al. (24)	0.89	0.659	0.49	(45–49)
Einarson et al. (25)	0.89	0.659	0.49	(45–49)
Barnes et al. (26)	0.696	NA	NA	AMICUS trial
Einarson et al. (27)	0.7/0.65*	0.485/0.469*	0.27	(21, 51, 52)
Einarson et al. (28)	0.890/0.840/0.795/0.790**	0.690/0.665/0.643/0.640**	0.49	(21, 51, 52)
Wiwat et al. (29)	0.69	NA	0.58	(22)
Nuhoho et al. (30)	0.89	0.659	0.49	(45–49, 53)
Aigbogun et al. (31)	0.88	0.74	0.53	(45, 54)
Németh et al. (32)	Not reported	Not reported	Not reported	(39)
Zhao et al. (33)	0.88	0.74	0.53	(45), expert opinion
Abdall-Razak et al. (34)	0.799	0.67	0.67	(45)
Dutina et al. (35)	0.919	0.604	0.604	(46)
Arteaga et al. (36)	0.916/0.865##	−0.358	−0.358	(46, 51)
Yi et al. (37)	0.92	0.74#	0.60	(45, 46)
Lin et al. (38)	0.88/0.75/0.75###	0.74/0.63/0.63###	0.53/0.53/0.42###	(45), expert opinion
Jin et al. (39)	0.80	0.67	NA	(45)

NA, not applicable.

^*Data presented as utility for patients receiving injection therapy monthly/utility for patients receiving injection therapy every 3 months.

^**Data presented as utility for patients receiving paliperidone 3-month injection/paliperidone 1-month injection/risperidone long-acting injection/haloperidol decanoate injection, oral olanzapine and clozapine.

^#Data refer to acute phase.

^##Data presented as utility for patients receiving paliperidone 3-month injection/paliperidone 1-month injection.

^###Data presented as utility for full compliance, partial compliance and non-compliance patients.